Programmed cell death-1(PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors have shown a lasting anti-tumor response and can improve the survival rate in several malignant tumors including kidney cancer, bladder cancer, melanoma, and lung cancer (8). This evidence concerns the gene CD274 and urinary bladder carcinoma.